From Surf Wiki (app.surf) — the open knowledge base
Diquafosol
Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010. It is formulated as a 3% ophthalmic solution of the tetrasodium salt.
Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.
References
References
- (April 16, 2010). "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan".
- (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Diquafosol — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report